CommercialCoverageMedium impact
Tibial Nerve Stimulation (TNS) for Voiding Dysfunction 8.01.22
Excellus BlueCross BlueShield·Urology, Neurology·Nervous Systems (Neurology)
Effective date
Apr 16, 2026
We identified it
Jun 20, 2026
Summary
Excellus BCBS updated their policy for Tibial Nerve Stimulation (TNS) for voiding dysfunction, effective April 16, 2026. The policy establishes specific criteria for coverage of percutaneous posterior tibial nerve stimulation (PPTNS) for urinary conditions, requiring failure of both conservative therapies (3+ months) and pharmacological treatments before approval.
Action Required
Before April 16, 2026: Billing team must update prior authorization requirements for PPTNS procedures to verify patients have failed both conservative behavioral therapies for at least 3 months AND pharmacological therapy (including at least 2 anticholinergic or beta-3 adrenergic agonist medications). Document that implanted TNS devices are investigational and not covered. Update treatment protocols to reflect 12 weekly sessions as standard, with monthly maintenance only if 50% improvement is documented.